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COVID-19 is an acute infectious respiratory distress syndrome (ARDS) 
caused by the novel coronavirus SARS-CoV-2. The disease is highly commu-
nicable and produces mild to severe symptoms, generating a high demand for 
intensive care and thousands of deaths. In March 2020, COVID-19 was de-
clared a pandemic and has already surpassed five million cases and 300,000 
deaths in the world. The natural history of the disease has still not been fully 
established, hindering the elaboration of effective clinical protocols and pre-
ventive measures. Nevertheless, the disease requires a systemic approach, 
since there is evidence of acute and chronic complications, in addition to the 
catastrophic effects on the population’s mental health. This highlights the need 
for a methodology that more effectively captures the effect of COVID-19, 
considering such aspects as severity, duration, and the potential to generate 
chronic complications that will increase the demands on Brazilian Unified 
National Health System (SUS). DALYs, or disability-adjusted life years, are 
thus an extremely useful indictor that adds mortality, an estimate of years 
of life lost (YLLs), and morbidity, an estimate of years of life lived with dis-
ability (YLDs). This article discusses the relevance and difficulties of study-
ing the burden of COVID-19 and its complications in the Brazilian context, 
highlighting the natural history of the disease and estimating indicators such 
as YLDs, considering the high burden of disease in planning strategies to deal 
with the consequences of COVID-19 after the pandemic. The article also dis-
cusses the future challenges to deal with the disease in the SUS and the effects 
on the calculation of DALYs. 
Coronavirus Infections; Potential Years of Life Lost; Indicator of Morbidity 
and Mortality; Primary Health Care 
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Definition and relevance of COVID-19
In December 2019, the World Health Organization (WHO) office in China 1 reported the first official 
case of a pneumonia, still of unknown cause, in Wuhan, Hubei province, triggering particular interest 
among health authorities. By late January 2020, a state of public health emergency of international 
concern had been declared. By February 2020, the acute respiratory distress syndrome (ARDS) that 
was spreading with exponential progression was named COVID-19 by World Health Organization 
(WHO) 1, and on March 11, 2020, WHO declared the disease a pandemic. By that time, COVID-19 was 
present in some 100 countries, with more than 100,000 confirmed cases of the disease, and specific 
measures were needed for its identification, prevention, and control 1,2,3.
COVID-19 is an infectious ARDS caused by the novel coronavirus, the etiological agent 
SARS-CoV-2. Other epidemics had been reported with similar etiological agents, such as 
SARS-CoV-1 and MERS, but none of them with such magnitude 2. SARS-CoV-2 presented particu-
larly rapid spread and increase of new cases.
In Wuhan, the indicator of transmissibility (R0), which indicates the speed of viral spread in 
humans, was 2.2 (95%CI: 1.4; 3.9), indicating that each infected person can infect two more persons 
on average through actual contact 4. In the recent literature, the R0 of SARS-CoV-2 varied from 1.95 
(95%CI: 1.4; 2.5) 1 to 6.5 (95%CI: 5.7; 7.2) 4, with an estimated mean R0 of 3.3 and median of 2.8 4. The 
observed variation is due to estimates at different moments in the outbreak of COVID-19 1,4.
Concerning pathogenesis, 70% to 80% of infected individuals are either asymptomatic or present 
mild symptoms of the disease. Still without consensus in the literature, an estimated 20% will develop 
the more severe form of the disease in hospital care and may reach 5%-10% in intensive care 1,5. 
Mean convalescence time is 19 days (2 to 5 days until the appearance of symptoms and 14 days after 
symptoms until recovery), but cases in intensive care take 3 to 6 weeks 1. Since the entire population 
is susceptible, a very rapid increase in the number of infected individuals will lead to an overload 
on hospital beds, procedures, and equipment 5,6. The risk factors associated with severity feature 
advanced age (over 60 years, especially for increased risk of mortality) and presence of comorbidities 
(cardiovascular diseases, obesity, diabetes, hypertension, pulmonary diseases, etc.), accelerating the 
progression of symptoms, with worse prognosis 4.
According to WHO data (https://www.covidvisualizer.com, accessed on 30/May/2020), the 
world had reported approximately 6 million confirmed cases of COVID-19, with more than 365,000 
deaths associated with the disease. By the same date, the Brazilian Ministry of Health had reported 
470,000 confirmed cases (incidence of 221.5 per 100,000 inhabitants) and nearly 30,000 deaths from 
the disease, with a case-fatality rate of 6% (mortality rate of 13.3 per 100,000 inhabitants), noting that 
the first case had been reported on February 26, 2020, and the first official death on March 17, 2020 
(Ministério da Saúde. https://covid.saude.gov.br/, accessed on 30/May/2020). The current scenario 
is due to Brazil’s adherence to the social distancing protocol recommended by the WHO and adopted 
since March 12, 2020 7.
Measurement of DALYs from COVID-19: reflections, limits, and possibilities
Despite the importance of measurement and analysis of morbidity and mortality for understanding 
the impact of COVID-19, we highlight the relevance of a methodology that more effectively computes 
how much this disease influences the population’s health status, considering such aspects as severity, 
duration, and the potential to generate chronic complications according to age bracket, sex, and loca-
tion, besides the impact on the Brazilian Unified National Health System (SUS).
Thus, an extremely useful indicator is disability-adjusted life years (DALYs), developed by Murray 
& Lopez 8,9 in the mid-1990s in the context of the Global Burden of Disease (GBD) study. The indicator 
is divided into two components: (1) mortality, estimated years of life lost (YLLs), and (2) morbidity, 
estimated as years lived with disability (YLDs).
Nearly three decades since studies on global burden of disease emerged 9, they have incorpo-
rated updates and methodological refinements 10,11. This period has witnessed intense debates on 
the methodological proposal for measuring DALYs, and various methodological refinements have 
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been incorporated. The field has also incorporated researchers, research groups, and institutions 
from throughout the world as collaborators in the various editions of the national/global estimates 
of GBD, under the coordination of Christopher Murray, who heads the core group of the Institute of 
Health Metrics and Evaluation (IHME), Washington University (Seattle, USA). There was a significant 
increase in the number of target diseases and sequelae, as well as the potential risk factors 8,10,12,13.
The challenges and the emergence/resurgence of new and old diseases require updates, new 
methodologies to estimate the years lived with disability (YLDs), often with an important degree 
of incompleteness, given the limited knowledge on the natural history of the disease, like arbovirus 
infections, more specifically Zika and chikungunya, and currently the SARS-CoV-2 pandemic. In 
addition, questions related to the specificities, given the economic and demographic characteristics 
and social inequalities, are still debated to reflect on the national/global estimates.
Brazil has conducted two national editions of the burden of disease study. The first was in the year 
1998 14,15,16 and the second in 2008 17,18,19, besides studies on specific diseases such as diabetes 20,21, 
hepatitis/cirrhosis 22,23,24, external causes 25,26,27, and neglected diseases 28. The last version of the 
Brazilian study features methodological refinements that underscore the originality of national stud-
ies, representing an important difference in relation to the GBD, more specifically in relation to the 
morbidity component (YLDs). In this sense, the two versions of the Brazilian Burden of Disease Study 
(1998 14 and 2008 17) cannot be compared directly, which would require the replication of method-
ological contributions for each disease 26.
In the case of COVID-19, the clinical and epidemiological panorama of the acute and chronic 
complications requires some time for execution. The available and necessary scientific literature for 
performing estimates of YLDs, given the short time since the onset of COVID-19 for investigation 
of recovered cases, points to challenges for calculating DALYs: mapping acute and chronic complica-
tions of COVID-19 and the respective clinical and epidemiological parameters.
DALY is sensitive to the quality and precision of the information used as the data source to obtain 
inputs for estimates, as well as the weights assigned to the severity of measured chronic complications 
(measurements to be constructed), which currently introduces a relevant degree of uncertainty for 
DALYs in COVID-19. This emphasizes the relevance of studies with sensitivity analysis that assess 
the observed uncertainty in the estimates, considering the different scenarios of inputs and the deci-
sion-making process, for example, in relation to assigning weights and/or sources of information 29; 
as well as weighting according to the presence and amounts of associated comorbidities, which intro-
duce so much variability in YLLs 30. Two scenarios of possible sources could thus be considered: (a) 
official data from the State Health Departments/Brazilian Ministry of Health (Ministério da Saúde. 
https://covid.saude.gov.br/, accessed on 30/May/2020) and (b) alternative sources such as the SIVEP-
Gripe database (http://info.gripe.fiocruz.br, accessed on 30/May/2020) and the Civil Registry of 
Deaths (Portal da Transparência. Painel registral. https://transparencia.registrocivil.org.br/especial-
covid, accessed on 23/Apr/2020). Based on these compositions of scenarios, sets of sensitivity analy-
ses could be performed: official data versus data corrected for underreporting, which would certainly 
involve differences in the final set of DALYs.
The DALY indicator has the further advantage of specific analysis by age structure, a significant 
risk factor for COVID-19, added to the presence/number of comorbidities, as seen in the study 
by Hanlon et al. 30 showing an important variation in YLLs by age, based on the presence of other 
preexisting chronic conditions. For example, there are 35 YLLs (on average) for men 50-59 years 
of age (without comorbidities) and 19 YLLs for those with five comorbidities, due to the lower life 
expectancy and lower incidence in this group with more comorbidities. Meanwhile, for those 80 years 
and older, the loss is 11 YLLs (without comorbidities) and 1.5 YLLs for 11 comorbidities, despite the 
higher risk and higher incidence in this age group.
Another relevant in the decision-making process for calculating YLDs is the challenge of defin-
ing the set of weights assigned to the severity of acute and chronic complications associated with 
COVID-19, given the current lack of complete knowledge on the natural history of the disease, its 
clinical and epidemiological horizon (which affects the duration), changes in the treatment protocol 
due to technological innovations from emerging studies at the global level, both to measure the effi-
cacy of known medicines and the search for new drugs and vaccines (which will mean the indicator 
of percentage of treated individuals, also incorporated into the YLDs).
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All these questions will have a direct impact on measurement of YLDs, translated as the time 
lived with disability associated with the underlying disease, given access to the treatment protocol, 
weighted by the severity of each acute or chronic complication 8,9.
Current and future problems: acute and chronic complications of COVID-19 and 
construction of the metric for burden of COVID-19
The essential elements for calculation of YLDs involve incorporation of the “lost” time resulting from 
the complications and their respective severities, compiled via the weights of the disabilities and dura-
tion of acute and chronic complications, even though the possible complications of COVID-19 have 
not been exhausted, given the need for more studies on cell tropism and pathogenic mechanism 31,32. 
The disease requires a systemic approach, given the evidence of possible complications in vital organs. 
Thus, the dissemination and thus the effects of SARS-CoV-2 in the body are extensive 33,34,35.
When the etiological agent SARS-CoV-2 enters the host organism, it binds to the angiotensin- 
converting enzyme-2 (ACE-2) receptor, allowing entry into the target cell and replication, triggering 
an immune response in the host and the first symptoms and clinical manifestations 35. Despite the 
known tropism of the virus for the upper respiratory tract and lung tissue, due to the portal of entry, 
other organs that also express this receptor can be affected 36, and the individual can develop other 
corresponding clinical manifestations 37.
To understand the distribution of the disease in the humans, Wu et al. 38 conducted studies on 
metabolomic and lipidomic alterations in which they demonstrated an apparent correlation between 
them and the development of COVID-19, indicating that the disease altered metabolism throughout 
the body, with effects ranging from the cellular level to various organ systems.
These metabolic alterations, due to the relative underlying susceptibility to the infectious process 
by endothelial deregulation from the inflammatory mechanism, reduce the vessels’ capacity to per-
form important regulatory functions 31,37. These alterations can thus lead to acute or chronic compli-
cations that are related to the more serious forms of the disease 30,31,37,39,40.
In the current scientific literature, the above-mentioned target organs include the lungs, but the 
lack of oxygen and the systemic inflammation can also acutely damage the kidneys 41 (27%), liver 42 
(50%), and gastrointestinal tract 43,44,45 (20%) and cause alterations in the coagulation cascade and 
hematopoietic system, heart, and cardiovascular system 46, brain and central nervous system (CNS) 47, 
and other organs 41.
As for acute complications 36, the propensity to develop blood clots from inflammation in these 
vessels, especially in the lungs, can account for the development of more severe forms of the disease, 
since the thrombi can play a direct and significant role in the gas exchange abnormalities and multi-
system organ dysfunction 31,32,37.
The central nervous system sequelae can be devastating, especially due to respiratory viral infec-
tions, since there are at least two known entry routes for the virus into the CNS, the bloodborne 
route mediated by ACE-2 receptors and the retrograde neuronal pathways and infection induced 
by neuropathic virus, which can explain the increase in the occurrence of stroke, behavior changes, 
and anosmia 31.
As for the heart and vascular system, the most frequently reported complications are acute car-
diac lesion, cardiac insufficiency, myocarditis, vascular inflammation, and cardiac arrythmias 39,40,48. 
The heart problems, associated with an increase in cardiac enzyme levels, can be related to a com-
bination of a significant systemic inflammatory response and vascular inflammation located at the 
arterial plaque 46.
 Renal insufficiency in COVID-19 patients has occurred due to increased serum creatinine and 
decreased glomerular filtration rate. SARS-CoV-2 infection can induce severe acute tubular necrosis 
and lymphocyte infiltration, causing more tubular damage via recruitment of macrophages to infil-
trate the interstitial tubule 34,48,50, potentially explained by ACE-2 receptor expression in the renal 
tubules 34,50.
Thrombotic alterations have been identified in COVID-19 patients 32,37,51,52, and thrombocy-
topenia has been associated with fivefold higher odds of developing the more severe form of the 
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disease 49,50. Studies show that COVID-19 can increase the risk of developing disseminated intra-
vascular coagulation 51. One can infer that deregulation of the coagulation cascade and the resulting 
formation of intra-alveolar or systemic fibrin clots are prominent findings in both COVID-19 and in 
other severe respiratory diseases 51.
The virus thus acts on a receptor that is involved in control of the circulatory system, acting on the 
small arteries, which leads to numerous acute complications 36. Therefore, when calculating YLDs, 
it is necessary to consider that the complications require practically a “complete burden of disease 
study”, with workup of clinical and epidemiological parameters for each of these conditions. A “more 
simplified” estimate would be to aggregate cases by differentiated severities and thus estimate the 
YLDs for COVID-19 in mild, moderate, and severe/ICU cases with complications. This lends consid-
erable complexity to the estimate. The same is obviously true for chronic complications in relation to 
the estimate of duration and weights of disabilities.
In this scenario in which the natural history of the disease is in constant evolution, it is also impos-
sible to determine all the chronic complications that COVID-19 survivors will experience. Thus, one 
cannot rule out that chronic complications will be related to the acute complications cited above, such 
as renal insufficiency, stroke, and liver failure, among others 37,38,39,47,48,51.
Mapping the chronic complications of COVID-19 and understanding their onset can draw on 
studies of severe pneumonias that evolve to acute respiratory distress syndrome (ARDS) 53, leading 
to scars that generally cause long-term respiratory problems and that increase the risk of heart attack 
and stroke 47. Patients following hospitalization for severe pneumonia with ARDS have presented 
fourfold higher risks of heart attack and stroke in the first year and 1.5 times higher in the nine sub-
sequent years.
Extremely severe COVID-19 patients who spend long periods in the ICU are prone to developing 
“intensive care syndrome” 53,54,55,56, characterized by a set of physical (muscle atrophy and weakness, 
50%), cognitive (79%), and mental alterations (28%) that jeopardize the quality of life for both patients 
and their caregivers 53,55.
As for cognitive impairment, the risk factors associated with this process feature the duration of 
delirium in the ICU, acute cerebral dysfunction (stroke, alcoholism), hypoxia (ARDS, cardiac arrest), 
hypotension (severe sepsis, trauma), respiratory insufficiency that requires prolonged mechanical 
ventilation, and the use of renal replacement therapy 54,55.
Neuromuscular weakness acquired in the ICU is the most frequent physical alteration, occurring 
in more than 25% of ICU survivors, with reduced mobility, recurrent falls, or quadriparesis 53,54.
Mental alterations include the risk of developing psychological changes that can exceed 60% 54 
with such symptoms as anxiety, depression, and posttraumatic stress 53,54,55.
Given the above, improving the patient’s quality of life after post-ICU hospital discharge encom-
passes a series of measures such as post-hospitalization physical therapy, nutritional care, and psy-
chological support 58. This supports the hypothesis of the impact on caregivers and increased costs 
associated with care in convalescent COVID-19 patients.
As reported above, SARS-CoV-2 has the potential for systemic coagulation 31,37 and thus reduced 
blood flow to the brain, causing CNS complications such as seizures, loss of consciousness, anosmia 
or loss of smell (5% to 10%), and “intense and prolonged delirium”, which can lead to long-term cog-
nitive impairment including memory deficit 47,53,54,56. In COVID-19, the delirium can be aggravated 
by the use of sedatives (benzodiazepines) 57 to treat the violent coughing attacks and the anxiety and 
discomfort from the breathing tube 47,53,54,56. The emerging literature also reports the following 
complications: symptoms similar to Kawasaki syndrome in children 58,59, Guillain-Barré syndrome 
60,61,62,63, and complications of the retina 64 and testes, the latter possibly affecting fertility 65.
All this underscores the importance of studies to measure the burden of disease in COVID-19, 
since temporary and permanent comorbidities place a growing demand on health services for follow-
up of these patients, both in primary and medium-complexity care, which historically display limits 
to patients’ access, with an impact on diagnosis, monitoring, and rehabilitation.
To date, the lack of knowledge on COVID-19 determinants and complications hinders 
the decision-making process for determining clinical and epidemiological parameters to calcu-
late YLDs and to define the associated weights of severity, which have such great influence on the 
indicator’s sensitivity.
Campos MR et al.6
Cad. Saúde Pública 2020; 36(11):e00148920
Mental health burden from COVID-19: where are we heading?
In addition to the acute and chronic complications cited in the previous section, the COVID-19 pan-
demic also creates a global scenario of risk factors for short and long-term mental health problems. 
This situation impacts both patients (due to social isolation, quarantine, and/or medical treatment of 
COVID-19, especially prolonged hospitalization and intensive care) and the population under social 
distancing 7, creating an environment prone to mental health problems such as anxiety, depression, 
and feelings of helplessness and uncertainties about the future 66,67.
A special focus is thus needed on the mental health of target groups with heightened risks: health-
care workers, patients with prior psychiatric diagnoses, patients recovered from COVID-19, or the 
general population without mental health diagnoses but subject to becoming clinical cases 68.
Essential workers, especially in healthcare, will be overburdened by an environment of stressful 
work, contributing to the development of mental disorders like anxiety, post-traumatic stress disor-
der (PTSD), and burnout 66,67,69. This scenario means a major increase in the demand for psychiatric 
care, as well as care for individuals diagnosed with COVID-19, leading healthcare workers to require 
mental health care for themselves, to the extent that they are burned out from the work. This can lead 
to absenteeism and presenteeism, reducing the health system’s capacity to provide care when health-
care workers themselves fall ill. Care for the health of essential workers in the pandemic is essen-
tial for minimizing their burnout and thereby guaranteeing better conditions for them to perform 
their work.
Patients with mental disorders who were in psychiatric treatment before COVID-19 experience 
difficulty in accessing mental health services due to the pandemic, due to social distancing and the 
overload on the health system, and may have their clinical status aggravated by the feeling of loneli-
ness and isolation 66,67,69. Especially for severe patients, chronic or permanent sequelae may occur, 
leading in turn to mental disorders related to loss of physical capacity 70.
From the population perspective, especially in developing countries like Brazil, the economic 
impacts of measures to prevent transmission of the disease are being felt and will continue to be 
reflected in the rise in poverty, unemployment, and the homeless population 69. Untreated preexist-
ing mental health conditions may be aggravated and new conditions may emerge, leading us in turn 
to infer the increase in depression, anxiety, psychoactive substance abuse, self-harm, and suicide 
attempts 69,71. That is, worsening socioeconomic conditions can lead to an increase in the prevalence 
of mental complications in the post-pandemic scenario.
The current scenario with the COVID-19 control strategy can exacerbate family conflicts and 
isolate the family from external environments, fueling an increase in domestic violence and abuse of 
vulnerable family members 66,69,70,71, producing hostile environments that can be prone to the devel-
opment of psychological traumas.
A potential strategy is to restructure the dynamics of mental health care during pandemics, with 
online psychological care and collective care approaches as possible alternatives for dealing with the 
increase in this demand 72,73.
COVID-19 thus affects all of society, generating a favorable space for mental disorders 
66,67,68,69,70,71,74, and one can logically expect a pandemic of mental disorders during and after the 
COVID-19 pandemic.
Considering that the burden on mental health historically adds the largest share of YLDs (an 
estimated 50%) 8,10,14,18 and that the current COVID-19 pandemic intensifies this group of chronic 
diseases, it is essential to investigate the clinical and epidemiological parameters for measurement of 
these conditions (YLDs).
Importantly, the DALY indicator, as discussed above, consists of two components, mortality 
(YLLs) and morbidity (YLDs). However, health system programming and administration traditionally 
uses only the mortality indicator, which is not effective for mental health. This highlights the need for 
measurement of YLDs, which will impact programming of human resources and installed capacity 
for care for these disorders, since the construction of this indicator is capable of evoking this compo-
nent’s weight, so relevant in these groups.
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Future challenges for dealing with COVID-19 in the SUS and reflections on DALYs
The literature on estimates of the global burden of disease emphasizes the importance of the DALY 
indicator in measuring mortality and morbidity in the same metric. The component that measures 
temporary and permanent disabilities even represents the strategic thrust to support planning, pro-
gramming, and the economic impact on the health system, where it is possible to identify the differ-
ences between the public SUS and the private healthcare system.
Studies on burden of disease in Brazil for the reference years 1998 14 and 2008 17 and the esti-
mates by the WHO for the years 2000, 2010, and 2016 12 presented results for the morbidity compo-
nent (YLDs) of some 50% 12,13,75. This percentage means that half of the burden of disease in Brazil 
expresses the weight of living with the temporary and permanent sequelae from the diseases included 
in the studies. A major share of the sequelae are complications from chronic noncommunicable dis-
eases, which however does not rule out the complications related to chronic infectious diseases such 
as Chagas, AIDS, Zika, and particularly those related to COVID-19 and still not completely defined, 
given the partial knowledge on the natural history of this novel disease.
Complications from diseases vary in the degree of impairment to the persons’ autonomy, and 
they influence quality of life, often leading to early retirement and increased demand for medium and 
high-complexity care, which in turn show unequal distribution across the country’s territory, further-
ing limiting access to services and resulting in late diagnosis and limited capacity for rehabilitation, 
even though the public SUS guarantees universal and comprehensive access to the health system 76. 
The passage of Constitutional Amendment n. 95 (EC95, Portuguese) by the Brazilian Congress further 
reduced the investment in health for an already chronically underfunded SUS 77, reducing the quality 
of public health services and further limiting patients’ access. This scenario was aggravated by the 
reduction of budget funding for policies in social protection and promotion, besides closing family 
health clinics and fueling the resurgence of previously eliminated diseases like measles 78.
The COVID-19 epidemic has hit Brazil in a scenario of unemployment, impoverishment, and 
other risk factors related to transmissibility of the disease. Economic crises can facilitate the transmis-
sion of infectious diseases and hinder the implementation of control measures which, in the context 
of a pandemic, can express mortality comparable to that of wartime situations, further exacerbating 
the economic crisis 78. According to Sands et al. 79, infectious diseases are one of the greatest risks 
to economic growth, although the economic recession’s impact on the control of infectious diseases 
depends on the context, mapping of risk areas, the situation of vulnerability, and political decisions 
on financing, for example in the case of a possible repeal of the budget freeze implemented by EC95 
in order to increase the funds needed to bolster the budget for health and social protection 80.
The individual and collective conditions (socioeconomic and demographic) for dealing with the 
public health crisis caused by COVID-19 are heavily unequal in Brazil. According to data from a Bra-
zilian study 81, while the South and Southeast proportionally concentrate the majority of specialized 
human resources (critical and respiratory care physicians) and hospital equipment (ICUs and mechan-
ical ventilators), the North and Northeast have lower parameters in relation to their shares of the 
national population. The study thus suggests that given this discrepancy in the availability of installed 
capacity and human resources, the response to the crisis is unequal, impacting the COVID-19 case-
fatality rates and the collapse of the SUS.
In addition, in relation to sociodemographic differences in the response to the pandemic, 
the national seroprevalence sample survey EPICOVID 82 demonstrates the significant differen-
tiation according to self-reported race: 0.7% prevalence in whites, 2.3% in browns, and 4.3% in 
indigenous people.
In the more specific context, in the city of Rio de Janeiro, COVID-19 case-fatality was 12%, rang-
ing from 9.2% in neighborhoods “without favelas” to 19.5% in those with an “extremely high concen-
tration of favelas” (more than 50% of favelas in the neighborhood). High COVID-19 case-fatality in 
these vulnerable territories may indicate low testing and higher severity associated with preexisting 
diseases or risk factors, besides difficult access to healthcare 83.
Measures to control the pandemic will have substantial short and long-term consequences; the 
restrictions from physical distancing and quarantine will reduce physical activity and increase other 
unhealthy lifestyles, leading to an increase in risk factors (smoking, alcohol consumption, sedentary 
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behavior, and obesity) for chronic noncommunicable diseases, with the exacerbation of clinical symp-
toms. Alterations in routine outpatient and inpatient care, such as 84: cancellation/ postponement of 
appointments or prenatal follow-up and/or postponement of elective surgeries, reduction of cover-
age, and delays in the vaccination calendar, among others, will have important implications for health 
of the population as whole, overloading the health system.
Even after overcoming the pandemic’s emergency phase, when the number of cases and deaths 
wanes, there is still the challenge of dealing with the increased demand on the SUS for diagnosis, treat-
ment, and rehabilitation of recovered patients from the possible chronic complications of COVID-19, 
such as: increased demand for rehabilitation services due to respiratory complications; consultations 
and psychotherapies both for “new” and prior psychiatric cases aggravated by difficult access during 
the pandemic; overload on care by cardiologists due to the accumulated consultations postponed in 
the protocol for control to avoid transmission and increased incidence of cardiovascular conditions 
from COVID-19, with increased risk of stroke and heart attack; and aggravation of the scenario of 
drug therapy and elective surgeries for chronic diseases due to rescheduling of prescriptions.
This all underscores the enormous current and future effects of the COVID-19 pandemic on the 
SUS, and the metrics to be constructed need to consider these aspects. Thus, the timing and natural 
history of the disease are essential elements for constructing the components (YLL and YLD) of DALY. 
Without this, the uncertainty can compromise the indicator’s estimates. The complications associated 
with COVID-19 not only add to those related to other diseases, but represent an even greater burden 
for health services and families 85. The focus on the importance of the burden of morbidity (YLDs) 
will thus be strategic in organizing networks of care and planning and programming health actions.
Currently, considering the debate on the control measures deployed thus far, it is necessary deter-
mine which epidemiological surveillance actions in the territory represent a structuring strategy, 
together with primary healthcare (PHC), for monitoring COVID-19 infection 84,85,86. Proper moni-
toring of the disease in the country also provides essential information for estimating the classical 
epidemiological parameters needed to construct the DALY.
A suggested strategy for dealing with the pandemic and post-pandemic to generate more precise 
clinical and epidemiological parameters of the disease and its sequelae, necessary for the DALY, is 
to guarantee appropriate action by PHC in screening and monitoring infected individuals and their 
contacts, applying social distancing strategies recommended by family health teams and work by 
community health agents, according to guidelines from the Department of Primary Health Care 
(SAPS, in Portuguese), Brazilian Ministry of Health 86,87. That is, recommendations for organization 
of COVID-19 care in PHC in the SUS 88 should be followed, based on identification of suspected 
cases, with household contacts and if possible community contacts in the previous 14 days to orient 
home isolation for 14 days, reducing transmission and avoiding simultaneous generation of serious 
cases and overload on the SUS.
The system requires strong PHC in order to flatten the pandemic’s curve and ensure sufficient 
ICU beds 89 and a safer and more efficient alternative path for dealing with the pandemic. As for the 
current control strategies’ effectiveness, the longer person-to-person transmission is stretched out, 
the more manageable the situation will be for the SUS.
According to Vitória & Campos 89, adequate guidelines for PHC in dealing with the pandemic 
consist of: (1) guaranteeing safe access to basic healthcare units (UBS in Portuguese) with adjustment 
of the physical infrastructure and online PHC (with separation of an exclusive entrance for COVID 
patients or use of tents); (2) guaranteeing safety in immunizations; (3) protecting healthcare workers 
(orienting and providing use of personal protective equipment); (4) guaranteeing continuity of care 
over time; (5) strengthening the family approach; and (6) strengthening the community approach.
On the specific item (4) concerning continuity of care over time, the following are crosscutting 
strategies: telecare, which avoids public circulation of symptomatic individuals who only require 
orientation; and keeping the family health teams alert to the evolution of patients with low oxygen 
saturation (but without symptoms) and/or aggravation of their clinical condition. In item (5), on the 
family approach, PHC should orient families on caring for their patients, providing adequate nutri-
tion, sufficient liquids, and medication for fever and avoiding transmission to others. In item (6), the 
community approach, the UBS know the vulnerable families in their respective territories, those with 
heavy indoor crowding, for whom alternative places for quarantining are necessary to avoid further 
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transmission. The family health teams thus have key elements that allow better analysis and interpre-
tation of risks and vulnerabilities of individuals, families, and the community.
Finally, failures in access to diagnosis have an important impact on the morbidity and mortality 
profile, expressed in the increased demand on medium and high-complexity services. And based on 
an accurate diagnosis of COVID-19’s epidemiology and particularly that of its chronic complications 
via estimation of DALYs, it is possible to provide backing to draft new strategies and policies to deal 
with the pandemic. However, this goal will only be achieved with the appropriate knowledge, appre-
ciation, and financing of the SUS and its workers, especially in primary healthcare.
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Resumo
A COVID-19 é uma síndrome respiratória aguda 
grave (SRAG) infecciosa, causada por coronavírus. 
A doença tem alta transmissibilidade e ocasiona 
sintomas leves a graves, gerando elevada demanda 
por cuidados intensivos e milhares de óbitos. Em 
março de 2020, a COVID-19 foi caracterizada co-
mo pandemia e já soma mais de 5 milhões de casos 
e 300 mil óbitos pelo mundo. A história natural da 
doença ainda não é bem estabelecida, dificultando 
a elaboração de protocolos clínicos eficazes e me-
didas de prevenção. Apesar disso, pode-se afirmar 
que é uma doença de abordagem sistêmica, já que 
há evidências de complicações agudas e crônicas, 
além de efeitos catastróficos na saúde mental da 
população. Destaca-se então a necessidade de uma 
metodologia que capte de forma mais efetiva os 
efeitos da COVID-19, considerando aspectos como 
sua gravidade, duração e potencial de gerar com-
plicações crônicas que aumentarão as demandas 
no Sistema Único de Saúde (SUS). Nesse sentido, 
é de extrema utilidade o indicador DALY, ou anos 
de vida perdidos por morte prematura ajustados 
por incapacidade (DALY), que agrega a (1) mor-
talidade – estimativa dos anos de vida perdidos 
(YLL) e (2) morbidade – estimativa dos anos vi-
vidos com incapacidade (YLD). Este artigo discute 
a relevância e as dificuldades de estudar a carga 
da COVID-19 e de suas complicações, no contexto 
brasileiro, ressaltando a importância de caracteri-
zar a história natural da doença e estimar indica-
dores como o YLD, que considerem a alta carga de 
morbidade no planejamento de estratégias para li-
dar com as consequências da COVID-19 pós-pan-
demia. Discute-se também os desafios futuros para 
o enfrentamento da doença no SUS e reflexões so-
bre o cálculo do DALY.
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Resumen
La COVID-19 es un síndrome respiratorio agudo 
grave (SRAG) infeccioso, causado por coronavirus. 
La enfermedad posee una alta transmisibilidad y 
ocasiona de síntomas leves a graves, generando 
una elevada demanda de cuidados intensivos y 
millares de fallecimientos. En marzo de 2020, la 
COVID-19 se caracterizó como pandemia y ya 
suma más de 5 millones de casos y 300 mil falle-
cimientos por el mundo. La historia natural de la 
enfermedad todavía no ha sido bien establecida, 
dificultando la elaboración de protocolos clíni-
cos eficaces y medidas de prevención. A pesar de 
eso, se puede afirmar que es una enfermedad de 
abordaje sistémico, ya que existen evidencias so-
bre complicaciones agudas y crónicas, además de 
efectos catastróficos en la salud mental de la po-
blación. Se destaca entonces la necesidad de una 
metodología que capte de forma más efectiva los 
efectos de la COVID-19, considerando aspectos 
como su gravedad, duración, potencial de generar 
complicaciones crónicas que aumentarán las de-
mandas en el Sistema Único de Salud (SUS). En 
este sentido, es de extrema utilidad el indicador 
DALY o años de vida perdidos por muerte prema-
tura ajustados por incapacidad, que agrega la (1) 
mortalidad – estimación de los años de vida per-
didos (YLL) y (2) morbilidad – estimación de los 
años vividos con incapacidad (YLD). Este artículo 
discute la relevancia y las dificultades de estudiar 
la carga de la COVID-19 y sus complicaciones, en 
el contexto brasileño, resaltando la importancia de 
caracterizar la historia natural de la enfermedad y 
estimar indicadores como el YLD, que consideren 
la alta carga de morbilidad en la planificación de 
estrategias para lidiar con las consecuencias de la 
COVID-19 pospandemia. Se discuten también los 
desafíos futuros para el combate de la enfermedad 
en el SUS y reflexiones sobre el cálculo del DALY. 
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